EOLS 6.50 ▲ 4.17% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Evolus Inc.

    NASDAQ: EOLS · Real-Time Price · USD
    6.50
    0.26 (4.17%)
    At close: Oct 03, 2025, 3:59 PM
    6.53
    0.46%
    After-hours: Oct 03, 2025, 06:05 PM EDT
    4.17%
    Bid 6.26
    Market Cap 420.46M
    Revenue (ttm) 277.49M
    Net Income (ttm) -61.99M
    EPS (ttm) -0.98
    PE Ratio (ttm) -6.63
    Forward PE 22.29
    Analyst Buy
    Dividends n/a
    Ask 6.7
    Volume 764,175
    Avg. Volume (20D) 1,371,806
    Open 6.25
    Previous Close 6.24
    Day's Range 6.25 - 6.55
    52-Week Range 5.71 - 17.82
    Beta 1.04
    Ex-Dividend Date n/a

    About EOLS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol EOLS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for EOLS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Evolus Inc. is scheduled to release its earnings on Nov 5, 2025, after market closes.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    -28.51%
    Evolus shares are trading lower after the company ... Unlock content with Pro Subscription
    2 months ago
    -2.2%
    Evolus shares are trading lower after the company missed Q2 estimates and lowered its FY25 sales guidance.
    news image

    3 weeks ago · businesswire.com

    Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qu...

    news image

    3 weeks ago · businesswire.com

    Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

    NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of...

    news image

    1 month ago · businesswire.com

    Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

    NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline r...

    news image

    1 month ago · businesswire.com

    Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

    NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submit...

    news image

    1 month ago · businesswire.com

    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in August...

    news image

    2 months ago · zacks.com

    Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates

    Evolus, Inc. (EOLS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.07 per share a year ago.

    news image

    2 months ago · seekingalpha.com

    Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript

    Evolus, Inc. (NASDAQ:EOLS ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants David Moatazedi - President, CEO & Director Nareg Sagherian - Head of Global Investor Relati...

    news image

    2 months ago · businesswire.com

    Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

    NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of...

    news image

    2 months ago · zacks.com

    Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline

    Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    2 months ago · businesswire.com

    Evolus to Report Second Quarter Financial Results on August 5, 2025

    NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...

    Add to Watchlist